Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-VEGF agent + antiviral eye drops
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Ophthalmic, Intrastromal
01
Overview
This combination therapy consists of an intrastromal injection of a vascular endothelial growth factor (VEGF) inhibitor and topical antiviral eye drops. Developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University, the regimen is designed to treat corneal neovascularization (CNV) resulting from herpes simplex keratitis (HSK). The anti-VEGF agent targets and inhibits the signaling pathways responsible for pathological vessel growth in the corneal stroma, while the antiviral medication addresses the primary viral infection. This dual approach aims to reduce corneal opacity and improve visual outcomes by simultaneously treating the cause and the complication of the disease.
- Other names
- Intrastromal anti-VEGF injection and topical antiviral eye drops
02
Targets
ANGPT2 (Angiopoietin-2)PGF (Placental Growth Factor)DNA polymerase familyVEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on anti-VEGF agent + antiviral eye drops.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-VEGF agent + antiviral eye drops.